证券代码：301089 证券简称：拓新药业 公告编号：2025-061 拓新药业集团股份有限公司 关于召开2025年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 拓新药业集团股份有限公司（以下简称"公司"）第五届董事会第九次会议 审议通过了《关于提请召开2025年第三次临时股东会的议案》，决定于2025年12 月18日（星期四）上午9:00召开2025年第三次临时股东会。现将有关情况通知如 下： 一、召开会议的基本情况 1、股东会届次：2025年第三次临时股东会 2、股东会的召集人：公司董事会 3、会议召开的合法、合规性：召开本次会议的议案已于2025年12月2日经公 司第五届董事会第九次会议审议通过，本次会议的召集程序符合有关法律、法规、 规范性文件和《拓新药业集团股份有限公司章程》的规定。 4、会议召开的日期、时间 （1）现场会议时间：2025年12月18日（星期四）上午9:00 （2）网络投票时间：2025年12月18日（星期四） 其中，通过深圳证券交易所交易系统进行网络投票的时间为2025年12月18 日9:15-9:25，9 ...

证券代码：301089 证券简称：拓新药业 公告编号：2025-060 拓新药业集团股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事会会议召开情况 拓新药业集团股份有限公司（以下简称"公司"）第五届董事会第九次会 议通知于 2025 年 11 月 29 日以电话、邮件等方式向各位董事发出，会议于 2025 年 12 月 2 日以现场会议结合通讯形式在公司会议室召开。本次会议由公 司董事长杨西宁先生召集并主持，应出席会议的董事 9 人，实际出席会议的董 事 9 人，其中以通讯形式出席会议的董事 1 人，为咸生林先生，公司高级管理 人员列席了会议。 本次会议的召集、召开及表决符合《中华人民共和国公司法》及《拓新药 业集团股份有限公司章程》（以下简称《公司章程》）的有关规定，会议合法 有效。 表决结果：7 票赞成，0 票反对，0 票弃权，关联董事杨西宁、杨邵华回避 表决。 2、审议通过《关于公司及子公司向银行申请综合授信额度的议案》 经与会董事审议，同意公司及子公司根据业务发展需要，向银行申请综合 授信额度不超 ...

Core Viewpoint - The company plans to invest in a new biomanufacturing base for APIs and health dietary supplements in collaboration with the local government, aiming to enhance production efficiency and profitability [1] Investment Details - The total investment for the project is 420 million yuan, with approximately 300 million yuan allocated for fixed asset investment [1] - The land for the project will be provided by the local government, and the company will acquire the land use rights through market transactions or leasing [1] Project Construction - The project will involve the construction of production facilities and supporting infrastructure on newly purchased land in the Tokto Economic Development Zone [1] - Upon completion, the project is expected to help the company reduce production costs, expand profit margins, and improve its industrial chain layout [1] Strategic Benefits - The investment is anticipated to enhance the company's core profitability and sustainable development capabilities [1]

证券代码：301089 证券简称：拓新药业 公告编号：2025-067 拓新药业集团股份有限公司 关于全资子公司拟与托克托县人民政府签订项目投资协议 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、项目投资概述 拓新药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 2 日召开 的第五届董事会第九次会议审议通过了《关于全资子公司拟与托克托县人民政府 签订项目投资协议的议案》。公司子公司拓新药业（内蒙古）有限公司（以下简 称"乙方"）拟与内蒙古自治区托克托县人民政府（以下简称"甲方"）签署《内 蒙古自治区托克托县拓新药业（内蒙古）有限公司原料药及健康膳食补充剂生物 制造基地建设项目投资协议》。 本次拟投资协议不构成关联交易，也不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。根据《深圳证券交易所创业板股票上市规则》《公司 章程》等相关规定，该事项在公司董事会决策权限范围内，无需提交公司股东会 审议。 二、交易对方的基本情况 建设规模：项目总投资为 4.2 亿元，其中固定资产投资 3 亿元左右 本次交易的交易对方为内蒙古自治 ...

Core Viewpoint - The A-share market experienced a significant rally on November 25, with the ChiNext Index rising nearly 2%, driven by a surge in flu-related stocks due to an increase in flu activity across the country [1] Group 1: Market Performance - The ChiNext Index saw a nearly 2% increase on November 25, indicating strong market performance [1] - Flu-related stocks, such as Jindike and Xinhua Pharmaceutical, reached their daily limit up, reflecting heightened investor interest [1] Group 2: Flu Activity and Sales Data - National flu activity has rapidly increased in November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Sales of Oseltamivir surged by 237% over the past week, while sales of Maviral (Sofosbuvir) increased by 180% [1] - Data from Meituan indicates that special flu medications in Beijing have seen a month-on-month growth exceeding 130%, with Maviral growing over 110% and Oseltamivir granules increasing by over 85% [1] Group 3: Investment Opportunities - According to Everbright Securities, the rising flu epidemic is likely to increase public and market attention, leading to a growth in demand for flu prevention and treatment products [1] - Investment opportunities are suggested in flu vaccines, virus testing, cold medications, and special antiviral drugs, as well as blood products as a response to complex epidemic situations [1]

证券日报网讯拓新药业（301089）11月24日在互动平台回答投资者提问时表示，截至2025年11月20日， 公司股东户数19047户。 ...

Core Viewpoint - Recently, Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. was established with a registered capital of 50 million yuan, indicating the company's expansion into various sectors including food additives and pharmaceuticals [1] Company Summary - Tuoxin Pharmaceutical has a registered capital of 50 million yuan [1] - The company's business scope includes the production of food additives, pharmaceuticals, health food, and food sales, as well as the import and export of pharmaceuticals [1] - Tuoxin Pharmaceutical is wholly owned by Tuoxin Pharmaceutical, reflecting a consolidated ownership structure [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has obtained the FSSC 22000 certification for food safety management from the internationally recognized certification body Intertek [2] Group 1 - The certification signifies compliance with international food safety standards, enhancing the company's credibility in the biotechnology sector [2] - This achievement may open new market opportunities for the company, particularly in food safety and quality assurance [2] - The certification process reflects the company's commitment to maintaining high standards in its operations and products [2]

Core Points - The company announced the convening of the second extraordinary general meeting of shareholders for 2025 on November 13, 2025, to review the proposal regarding the resignation of independent directors and the election of new independent directors [2] - The company approved the election of Dong Hongjie and Yang Dejie as independent directors of the fifth board of directors [2] - Dong Hongjie has completed the required training for independent directors organized by the Shenzhen Stock Exchange and received the training certificate [2]

Core Points - The company announced the establishment of a wholly-owned subsidiary, Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. [2] - The board meeting to approve the investment in the subsidiary was held on October 28, 2025 [2] - The subsidiary has completed its business registration and obtained a business license from the Hohhot Tokto Economic Development Zone Management Committee [2]